This article first appeared on the Arent Fox LLP Health Care Counsel blog.
Following delays and much build up, the White House and the Department of Health and Human Services (HHS) have released their plan to address rising pharmaceutical prices and out-of-pocket costs directly impacting patients. The plan is known as the “American Patients First” program, as outlined in “The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs” (the Blueprint). As part of this, HHS has published a formal request for information (RFI) seeking public comment on the questions and issues raised in Section V of the Blueprint (summarized below). Comments are due to HHS on or before July 16, 2018. We encourage all interested stakeholders to utilize this opportunity to submit feedback to the agency.
One initial impression of the Blueprint is that many of the proposed solutions are not defined in great detail and will take time and agency (and in some cases Congressional) action in order to implement. In addition, many of the solutions were previously articulated in President Trump’s 2019 budget, and do not reflect novel policy. Additionally, many of the issues raised in the Blueprint are familiar to those actively engaged in or following the drug industry, but will require active engagement between HHS and the industry to refine and address.
http://ncbarblog.com/wp-content/uploads/2018/06/Blog-Header-1-1030x530.png00NCBARBLOGhttp://ncbarblog.com/wp-content/uploads/2018/06/Blog-Header-1-1030x530.pngNCBARBLOG2018-06-11 15:44:352018-07-20 21:59:00White House ‘Blueprint to Lower Drug Prices’: Large Aspirations, Little Detail